Figure S4 from CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors
Year: 2025
Type: other
Abstract: Supplementary Figure S4. Impact on DNA replication, cell cycle, and apoptosis with PARP inhibitor treatment in BRCA2 wildtype and mutant cells – related to Figure 5. A) Graph showing quantification of % EdU-positive ‘S’ phase cells. DLD-1 BRCA2 mutant control or POLB knockout cells treated with 500 nM niraparib for 5 days followed by staining with Click-iT EdU flow cytometric assay. FACS data was analyzed by FloJo software. B) Histogram plots of cell cycle analysis using a propidium iodide assay in DLD-1 BRCA2 WT control or POLB knockout cells treated with 500 nM niraparib for 5 days (left). Quantification of each cell cycle phase (% cells) across all treatment conditions is shown in the graph (right). C) FACS plots showing apoptosis analysis with Annexin-V/PI staining in DLD-1 BRCA2 WT control or POLB knockout cells treated with 500 nM niraparib for 7 days (left). Quantification of % apoptotic cells (annexin V positive + annexin-V/PI positive) is shown for all the conditions tested (right).
Authors: Katherine Lazarides, Justin L. Engel, Michele Meseonznik, Tianshu Feng, Ashley H. Choi, Yi Yu, Shangtao Liu, Samuel R. Meier, Hongxiang Zhang, Binzhang Shen, Robert Tjin Tham Sjin, Douglas A. Whittington, Brian J. McMillan, Brian Doyon, Xuewen Pan, Erik Wilker, Alan Huang, Jannik N. Andersen, William D. Mallender, Madhavi Bandi
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4413905558